+14 more
Interpret the survival outcome for this patient with or without surgery
analyse_media
analyse_media
analyse_media
analyse_media
analyse_media
Searching PubMed
distal cholangiocarcinoma peritoneal metastasis survival prognosis
Searching PubMed
cholangiocarcinoma stage IV pulmonary skeletal metastasis overall survival
Searching the Web
distal cholangiocarcinoma stage 4 peritoneal carcinomatosis liver metastasis pulmonary bone metastasis median survival without surgery 2024
Searching PubMed
cholangiocarcinoma distant metastasis overall survival chemotherapy gemcitabine cisplatin
Searching the Web
distal cholangiocarcinoma unresectable metastatic survival prognosis CA19-9 1000 gemcitabine cisplatin durvalumab 2024 2025
I now have all the information needed. Let me synthesize the complete clinical picture and survival analysis.
Patient Summary: Kami Sherpa / Karma Sherpa, 58-60 years, Female/Male (two related family members appear in these records; the primary patient is Kami Sherpa, Female, ~60 yrs)
Complete Clinical Picture
Diagnosed Condition
Metastatic Distal Cholangiocarcinoma (Bile Duct Cancer) - Stage IVB / M1 disease
The impression from the detailed CT/CEMRCP is: "Marked CBD dilatation with abrupt distal cut-off, suspicious for an obstructing distal biliary cholangiocarcinoma."
Extent of Disease - Metastatic Burden (M1 - Stage IV)
| Site | Findings |
|---|---|
| Primary tumor | 21 x 16 mm periductal mass at mid-CBD, causing 29 mm CBD dilatation with abrupt cut-off; intrahepatic biliary dilatation |
| Pancreatic tail lesion | 27 x 23 mm heterogeneous lesion (likely direct extension or nodal/metastatic deposit) |
| Liver metastases | 29 x 28 mm (Seg II/III) + 10 x 9 mm (Seg 6) - multiple hepatic deposits |
| Peritoneal carcinomatosis | Diffuse omental caking, nodularity, gross ascites - "highly suggestive of peritoneal carcinomatosis" |
| Pulmonary metastases | Multiple bilateral GGOs and nodules; 14 x 11 mm pleural/parenchymal nodule along right major fissure - suspicious for pulmonary metastases |
| Skeletal metastases | Sclerotic lesions at L2 and D11 vertebral bodies - suspicious for skeletal metastases |
| Duodenum | Infiltrative lesion in D1 causing mild luminal narrowing; biopsy taken for HPE |
| Esophageal varices | Grade I (4 varices) - likely portal hypertension from liver involvement |
Tumor Markers
| Marker | Value | Normal | Significance |
|---|---|---|---|
| CA 19-9 | >1000 IU/mL | 0-39 | Massively elevated - ~25x upper limit; strongly associated with biliary tract cancer |
| CEA | 139 ng/mL | 0-5 | Markedly elevated - ~28x upper limit |
A CA 19-9 >1000 IU/mL in the context of biliary obstruction and peritoneal spread represents an extremely aggressive tumor burden.
Blood Count Abnormalities
- Hemoglobin 10.5 g/dL (low - normocytic anemia of chronic disease/malignancy)
- HCT 29.1% (significantly low)
- Neutrophilia 76.4% (stress response/infection/tumor)
Survival Interpretation: Without Surgery vs. With Surgery
THIS PATIENT IS NOT A SURGICAL CANDIDATE
The following features make curative surgery (Whipple/hepatopancreaticoduodenectomy or biliary resection) absolutely contraindicated and technically impossible:
- Liver metastases (multiple segments) - precludes curative hepatic clearance
- Peritoneal carcinomatosis with gross ascites - disseminated disease
- Pulmonary nodules suspicious for lung metastases
- Vertebral metastases (L2, D11)
- Duodenal infiltration
- Esophageal varices suggesting portal hypertension from hepatic involvement
- Anemia (Hb 10.5) indicating poor physiological reserve
Surgical resection for cholangiocarcinoma requires complete (R0) resection with clear margins. Distant metastases (M1 disease) are an absolute contraindication to curative surgery. This patient has M1 disease at 5 separate distant sites.
Survival Without Surgery (Best Supportive Care / Palliative Chemotherapy)
| Scenario | Median Overall Survival |
|---|---|
| Best supportive care alone (no treatment) | 2-4 months |
| First-line Gemcitabine + Cisplatin (standard) | ~8-12 months |
| Gemcitabine + Cisplatin + Durvalumab (TOPAZ-1 regimen, 2022) | ~12.8 months (vs. 11.5 for chemo alone); 24-month OS rate ~24.9% |
| Stage IV biliary tract cancer overall | Median 6-12 months with treatment |
| Peritoneal carcinomatosis from GI/biliary cancer | 4-6 months with systemic chemotherapy alone |
In this patient's case, given the 5-site metastatic spread (liver + peritoneum + lung + bone + duodenum) and CA 19-9 >1000, the realistic prognosis is toward the lower end of this range - approximately 4-8 months with chemotherapy, or 6-8 weeks without any treatment.
The TOPAZ-1 trial established durvalumab + gemcitabine/cisplatin as the current standard for advanced biliary tract cancer; updated 2024 data showed a modest but meaningful OS benefit.
Survival With Surgery (Hypothetical / Not Applicable Here)
For context only - if this patient had been diagnosed at an early, resectable stage:
| Scenario | 5-year Survival |
|---|---|
| Curative resection (R0) of distal cholangiocarcinoma | 40-50% |
| R1 resection (positive margins) | 15-20% |
| Resection with node-positive disease | ~20-25% |
| Unresectable but no distant metastases | 5-year survival near 0% |
Surgery is not possible here. Even aggressive cytoreductive surgery (CRS-HIPEC) for peritoneal disease alone can extend survival by 2-3+ years in selected patients - but only when there is no distant hematogenous spread (lung, bone) and when the primary is controlled. This patient fails all criteria for CRS-HIPEC.
Summary Assessment
This is an advanced metastatic distal cholangiocarcinoma (Stage IVB) with:
- 5-site distant metastatic spread
- Massively elevated CA 19-9 (>1000) and CEA (139)
- Peritoneal carcinomatosis with gross ascites
- Pulmonary and skeletal metastases
- Duodenal infiltration
Surgery plays NO role in survival extension. The goal of care is palliative.
Realistic survival:
- Without chemotherapy: 6-8 weeks
- With palliative chemotherapy (GemCis ± durvalumab): 4-8 months median, with rare patients reaching 12-18 months
Immediate priorities should be:
- Biliary drainage (ERCP/stenting) for CBD obstruction to relieve jaundice and prevent cholangitis
- Biopsy result (HPE from D1) - awaited; needed to confirm histology and assess for actionable molecular targets (IDH1, FGFR2, HER2, MSI-H, TMB)
- Genetic/molecular profiling - FGFR2 fusions (pemigatinib/infigratinib), IDH1 mutations (ivosidenib), HER2 amplification, or MSI-H can open targeted therapy options that may modestly extend survival beyond the median
- Palliative chemotherapy discussion with oncology once performance status and bilirubin are optimized post-stenting
- Paracentesis for symptomatic relief of gross ascites
Disclaimer: This analysis is based on the radiological and laboratory information provided. A definitive prognosis requires histopathological confirmation of the primary tumor type, molecular profiling, and formal oncology assessment. The treating team's judgment supersedes any estimate provided here.
This is a shared conversation. Sign in to Orris to start your own chat.